Argo Wealth Advisory Boosts Amgen Holdings

Wealth management firm adds to its position in biotech giant Amgen

Apr. 17, 2026 at 7:27am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, tangible banking and financial machinery in shades of silver, steel, and chrome, conceptually representing the institutional investment and complex infrastructure behind the biotech industry.Argo Wealth Advisory's investment in Amgen reflects the firm's confidence in the biotech company's long-term growth potential.Thousand Oaks Today

Argo Wealth Advisory LLC, a financial advisory firm, acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to a recent SEC filing. The firm purchased 8,130 shares of the medical research company's stock, valued at approximately $2.66 million.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, focused on developing innovative human therapeutics. The company's commercial portfolio includes drugs used in oncology, nephrology, bone health, and cardiovascular disease. Argo Wealth Advisory's investment in Amgen reflects the firm's confidence in the biotech's long-term growth potential.

The details

According to the 13F filing, Argo Wealth Advisory's new Amgen position makes up 1.6% of the firm's overall portfolio, making it the 22nd largest holding. The purchase comes as Amgen's stock has seen solid performance, rising over 30% in the past year as the company continues to advance its pipeline of innovative biologic medicines.

  • Argo Wealth Advisory acquired the new Amgen shares in the fourth quarter of 2025.

The players

Argo Wealth Advisory LLC

A financial advisory firm that provides wealth management services.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

Argo Wealth Advisory's investment in Amgen reflects the firm's confidence in the biotech company's long-term growth potential as it continues to advance its pipeline of innovative biologic medicines. This purchase highlights the ongoing institutional interest in Amgen's stock as the company remains a leader in the biotechnology industry.